SciELO - Scientific Electronic Library Online

vol.49 número1Evolución histórica de las terapias antivirales en hepatitis crónica CEnfermedad de Creutzfeldt-Jakob en un paciente interpretado como encefalitis por herpes simple índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO


Revista Cubana de Medicina

versión On-line ISSN 1561-302X


BATISTA ALBUERNE, Noyde et al. Pharmacoeconomic study of antiemetic treatment in moderate and highly emethogenic chemotherapy. Rev cubana med [online]. 2010, vol.49, n.1, pp. 78-88. ISSN 1561-302X.

INTRODUCTION: the occurrence of nauseas and vomiting from chemotherapy are a significant complication. With appearance of antiserotoninergics 5HT3 (AR 5HT3) combined with steroids, have allowed a great control of these symptoms. OBJECTIVE: The aim of present paper is to asses in a economic way two alternatives for antiemetic tratment in cancer. METHODS: Some techniques of economical assessment to two alternatives of antiemetic treatment were used. For the first line, the cost minimization (CM) technique including the Granisetron hydrochloride schemes plus Dexamethasone and Ondansetron hydrochloride plus Dexamethasone. The cost-effectiveness analysis (CEA) assessed the alternative treatment after the scheme failure containing Ondansetron; we performed mean cost-effectiveness (MCE) and incremental cost-effectiveness (ICE) analyses, as well as the sensitivity analysis. RESULTS: For the treatment schemes used in the first line by patient with treatment, it is possible to achieve a saving of $0.76 in the moderately emethogenic chemotherapy (MECM) and the highly emethogenic chemotherapy (HECT). In MCE, the option using Ondansetron as a second line treatment for MECM is of $22.77 and of $4.034 for scheme uses Granisetron for each controlled case. Therapy for HECT using Ondansetron needs %65,41 and option using Granisetron needs $13.45 for each controlled patient, respectively. In the case of ICE a non-satisfactory result of $1.490 for scheme containing Ondansetron/controlled additional case in MECM, and of $3.140/controlled additional case for HECT. CONCLUSIONS: Antiemetic treatments with a higher economical save as first-line antiemetic therapy is that using Ondansetron, and in second line the scheme using Granisetron.

Palabras clave : Nauseas and vomiting; antiemetic; antiserotoninergics; pharmacoeconomy.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License